FDA Approved: WIXELA INHUB — Original Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approves Wixela Inhub as the generic inhaled fixed-dose combination of fluticasone propionate and salmeterol, manufactured by Mylan, under an original ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• WIXELA INHUB (Fluticasone propionate and salmeterol)

Snippet

ORIG AP for WIXELA INHUB (FLUTICASONE PROPIONATE AND SALMETEROL)